Khoury Tawfik, Sbeit Wisam
Department of Gastroenterology, Faculty of Medicine in the Galilee, Galilee Medical Center, Bar-Ilan University, Safed, Israel.
Cytopathology. 2021 May;32(3):326-330. doi: 10.1111/cyt.12962. Epub 2021 Mar 9.
Rapid on-site evaluation (ROSE) can improve adequacy rates of fine needle aspiration (FNA) and thus save operational costs. Our aim was to assess the cost-efficacy of ROSE performed during endoscopic ultrasound (EUS)-FNA of gastrointestinal lesions.
This was a retrospective cohort study of 156 patients who underwent EUS-FNA for pancreatic, submucosal upper gastrointestinal, and adjacent lesions at Galilee Medical Center between 2012 and 2017. The patient cohort was divided into group A (62 patients, 39.7%) who underwent EUS-FNA with ROSE, and group B (94 patients, 60.3%) without ROSE. Cost analysis was based on the additional expenditure of repeated EUS-FNA sessions needed to reach accurate and final diagnosis in the two groups.
The overall cost was significantly higher in group B ($121 422) as compared to group A ($72 861), including the ROSE cost. Additional EUS-FNA sessions were needed in 11.3% and 23.4% in groups A and B, respectively. The additional cost to achieve final pathological diagnosis was $7203 and $24 696 in groups A and B, respectively (P = .02), yielding a savings of $252 per EUS-FNA case by adding ROSE. Notably, adding ROSE to the EUS-FNA exam for gastrointestinal non-pancreatic lesions resulted in even higher savings per case ($682.40). Moreover, adding ROSE improved specimen adequacy to achieve final pathological diagnosis (odds ratio = 7.13, P = .0005).
EUS-FNA with ROSE was cost-effective. Incorporating ROSE into the clinical practice of EUS-FNA saves costs and improves specimen adequacy.
快速现场评估(ROSE)可提高细针穿刺抽吸活检(FNA)的取材成功率,从而节省操作成本。我们的目的是评估在胃肠道病变的内镜超声(EUS)引导下细针穿刺活检(FNA)过程中进行ROSE的成本效益。
这是一项回顾性队列研究,研究对象为2012年至2017年间在加利利医疗中心接受EUS-FNA检查的156例胰腺、上消化道黏膜下及相邻病变患者。患者队列分为A组(62例,39.7%),接受了EUS-FNA联合ROSE检查;B组(94例,60.3%),未接受ROSE检查。成本分析基于两组为达到准确最终诊断所需重复进行EUS-FNA检查的额外支出。
与A组(72,861美元)相比,B组(121,422美元)的总成本显著更高,其中包括ROSE的成本。A组和B组分别有11.3%和23.4%的患者需要额外进行EUS-FNA检查。A组和B组达到最终病理诊断的额外成本分别为7203美元和24,696美元(P = 0.02),通过增加ROSE,每例EUS-FNA病例节省252美元。值得注意的是,在胃肠道非胰腺病变的EUS-FNA检查中增加ROSE,每例病例节省的费用更高(682.40美元)。此外,增加ROSE提高了获得最终病理诊断所需标本的取材成功率(优势比 = 7.13,P = 0.0005)。
EUS-FNA联合ROSE具有成本效益。将ROSE纳入EUS-FNA的临床实践可节省成本并提高标本取材成功率。